BRAUN
8.2.2024 15:01:31 CET | Business Wire | Press release
From its home of IPL at its world-class innovation facility in Kronberg, Germany, the pioneering German electronics brand, Braun, today introduces the Braun Skin i·expert - the only fully connected IPL system that learns, adapts, and provides personalised feedback in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131964639/en/
Braun Skin i·expert. Fully connected IPL system. (Photo: Business Wire)
The revolutionary new Skin i·expert is Braun’s fastest way to 1 year of smooth skin*, all in the comfort of your own home.
A smart system that automatically adapts the energy to your skin tone providing you with an active real-time personalised treatment guidance per body area – Braun puts the power in your hands, offering a more comfortable hair removal experience with the new Braun Skin i·expert.
All IPL devices within the Braun portfolio have been designed to offer fast, safe, almost painless hair removal and undergo countless R&D tests and scientific research to deliver the desired results you want and need.
Braun IPL devices are assessed by independent dermatologists and certified by Skin Health Alliance's high skin safety standards
- Smart Coverage Feedback and Smart Head Recognition enables you to achieve your best results by guiding you in real-time to avoid missing any treatment areas.
- The only one** with automatic flash power adaptation to your unique skin tones and a Skin Check to achieve your best results, in full safety. Followed by personalized tips on how you can improve your next session.
- No need to worry about missing an appointment thanks to its built in Personal Progress Tracker and Smart Calendar that enables you to stay on track by automatically adapting the sessions schedule by showing you how many treatments you still have left. Take control of your hair removal journey with ease and at a fraction of the cost of going to a salon.
Braun’s new IPL smart device is a step change to your hair removal routine, it gives the power to you to get long-lasting smooth skin safely, easily from the comfort of your home.
Ahmed Aboulenein, Global Vice President at Braun, said: “At Braun's Kronberg Innovation Center, our team are committed to designing durable and user-centered innovations that leverage cutting-edge technologies. Our aim is to delight consumers and address their Grooming everyday problems effectively. By gathering insights and data from consumers worldwide, Braun has identified a need for solutions that enable users to achieve safe and long-lasting smooth skin at home. This valuable information has informed our latest breakthrough IPL innovation. Our ultimate objective is to empower consumers, allowing them to achieve safe, long-lasting smooth skin comfortably from the convenience of their own homes. What sets the new Braun Skin i-expert apart is its seamless integration of smart technology, connecting the IPL device with a dedicated mobile app. This comprehensive system learns and adapts to the user's specific skin and hair needs, guiding them step by step through the entire treatment process. It provides real-time personalized feedback, making it remarkably user-friendly for both experienced IPL users and beginners.”
Dr. Christine Dierickx, MD, a leading cosmetic dermatologist and Director of Skinperium Laser and Cosmetic Dermatology Clinic in Luxembourg, said: “Hair removal is one of the top three reasons why patients visit a dermatologist. Many consumers opt also for salons as they believe at-home devices are complicated and do not deliver the desired results. The Braun Skin i·expert is a unique device that has been developed after years of research. It features an intuitive smart system that makes hair removal extremely simple for consumers. The device learns use after use to provide a personalized experience tailored just to you. Additionally, the automatic flash power adapts to your unique skin tones to ensure you achieve the best results, in full safety. The new Braun Skin i·expert is set to revolutionize the way we remove hair at home.”
*Following the regimen. Individual results may vary.
**Shared technology with Cyden
***Further reading: Hattersley AM, Kiernan M, Goldberg D, Dierickx C, Sliney DH, Haedersdal M, et al. Assessment of adverse events for a home‐use intense pulsed light hair removal device using postmarketing surveillance. Lasers Surg Med. 2023;1–9. https://doi.org/10.1002/lsm.23650
Notes to editors
About Braun
Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to household appliances, watches and speakers. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131964639/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom